Click Here to Go Directly to the Story
Register/Subscribe
Home


 
 


U.S. EDITION
Full Table of Contents
Cover Story
Up Front
Readers Report
Corrections & Clarifications
Books
Technology & You
Economic Viewpoint
Economic Trends
Industry Insider
Business Outlook

News: Analysis & Commentary
In Business This Week
Washington Outlook
International Business
Industries
Developments to Watch
The Corporation
Government
Social Issues
Corporate Scoreboard

Legal Affairs
People
Finance
Industrial Management
BusinessWeek Lifestyle
BusinessWeek Investor
The Barker Portfolio
Inside Wall Street
Figures of the Week
Editorials


SMALL BIZ SUPPLEMENT May 21 Table of Contents


INTERNATIONAL EDITIONS
International -- Letter From Macedonia
International -- Spotlight on Brazil
International -- Readers Report
International -- International Outlook
International -- Asian Business
International -- European Business
International -- Latin America
International -- Finance
International -- Int'l Figures of the Week
International -- Editorials




MAY 21, 2001

INSIDE WALL STREET

Schering and Merck?

 
By Gene G. Marcial
Gene G. Marcial

  STORY TOOLS
Printer-Friendly Version
E-Mail This Story

Related Items Chart: Easier to Swallow


INSIDE WALL STREET

Schering and Merck?

All Dressed Up at Children's Place

AOL and Liberty: Tops in Media

Schering-Plough (SGP ) is looking puny: Its stock is one of the big losers among pharmaceuticals--down 33% this year. That has sparked speculation that Schering might become buyout bait. Rumors swirled when shares tumbled to 37, down from 56 in mid-February, after Schering disclosed that the Food & Drug Administration was looking into quality-control problems at its New Jersey and Puerto Rico plants.

CEO Richard Kogan insists Schering isn't for sale. But whispers persist: Drug giant Merck (MRK ), said to have talked to Schering about a buyout in mid-1999 and gotten a rebuff, approached Schering again after the FDA problems emerged, says an investment banker close to the industry. Schering has again turned Merck down, says this pro. But Merck isn't giving up: The banker says Merck has proposed a buyout price in stock of 65 a share, or $91 billion in total. He sees Schering ultimately coming around. Merck has a market cap of $176 billion, vs. Schering's $55 billion. Already, Merck and Schering have joint ventures in developing certain respiratory and cholesterol-reduction drugs.

Analyst Steven Tighe of Merrill Lynch figures Schering could be worth $42 to $72 a share, depending on whether the buyer is a financial group or a drugmaker. The price will vary, he says, depending on the buyer's revenues and Schering's earnings from 2001 to 2003. Tighe says a drug company could save a lot in buying Schering because it could cut costs on operations overlap. Such synergy, he says, could range from 3% to 8% of their combined sales. But both Schering and Merck declined comment as a matter of policy.



By Gene G. Marcial



Get BusinessWeek directly on your desktop with our RSS feeds.XML

Add BusinessWeek news to your Web site with our headline feed.

Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video.

To subscribe online to BusinessWeek magazine, please click here.

Learn more, go to the BusinessWeekOnline home page

Back to Top

MAY
TODAY'S MOST POPULAR STORIES

  1. These Men Could Kill SarbOx
  2. This Year's Holiday Hit Toy: Zhu Zhu Pets
  3. America's Best Place to Raise Your Kids
  4. Wall Street Plays Hardball
  5. Abercrombie & Fitch Bargains for a Rebound

Get Free RSS Feed >>
  MARKET INFO

Portfolio Service Update

Stock Lookup

Enter name or ticker



Media Kit | Special Sections | MarketPlace | Knowledge Centers
McGraw-Hill Cos.